問題 › 自社の事業価値は実際どれくらいでしょうか › HealthTech & Digital Health
デジタルヘルスにおける価値評価は、表面的なARRよりリスク共有収益を維持できるかどうかにかかっています。 デジタルヘルス企業にとって難しいのは構造的な理由です。成果リスクを契約する速度が、そのリスクを自社で担えるかを確認する速度を上回っています。測定期間は12か月、営業サイクルは11か月です。信頼できる回答にはリスク共有収益とエンゲージメント率を同時に見る必要がありますが、ほとんどの社内分析はここで止まります。2つの指標が異なるシステムに存在するためです。
デジタルヘルスにおける価値評価は、表面的なARRよりリスク共有収益を維持できるかどうかにかかっています。 デジタルヘルス企業にとって難しいのは構造的な理由です。成果リスクを契約する速度が、そのリスクを自社で担えるかを確認する速度を上回っています。測定期間は12か月、営業サイクルは11か月です。信頼できる回答にはリスク共有収益とエンゲージメント率を同時に見る必要がありますが、ほとんどの社内分析はここで止まります。2つの指標が異なるシステムに存在するためです。
創業者側は現在の収益で事業価値を判断します。買収側は契約取得後にリスク共有収益がどれだけ継続するかを評価します。これが、同じARRを計上する2社で提示額が大きく異なる理由です。
倍率を動かす要素は、リスク共有収益の割合、成果帰属を支えるエンゲージメント率、ロゴチャーンの水準、PMPMコスト控除後の粗利益率です。これらはいずれも、利益1ドル増加より倍率に影響します。
本当の作業は現在の収益を証明することではなく、倍率を抑えている要因がどれかを見極め、プロセス開始前に改善可能かを判断することです。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ リスク共有収益の割合が増加する一方、成果測定期間は12か月のまま、営業サイクルは11か月のままです。
✓ 成果帰属の多くがCEOや創業者個人の関係に依存しており、繰り返し可能な運用プロセスに移行していません。
✓ 収益の大部分が、チャーン上昇またはエンゲージメント低下を示すロゴに集中しており、PMPMと粗利益率に直接影響します。
通常、事態を悪化させる対応です。 売却前年に粗利益率を改善しても、リスク共有収益やエンゲージメント率をそのままにしておくことです。この方法では価値を高められるケースはまれです。
It is for you if you run or finance a digital health company and you are within a few years of a transaction and have never had the earnings normalised. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Quick Market Scan · sample company profile
The move. Convert 180 existing employer relationships into $11.7M incremental outcomes-contingent revenue by Month 24 without new-plan procurement.
The leak it closes. $6.5M device leakage reduced by shifting kit cost to employer opt-in, improving gross margin 7 points on employer cohort
The assumption it rests on. 180 employers accept outcomes-contingent terms at 45% at-risk share — the engine put the probability at 0.7.
| Investment required | $0.6–0.9M total (2 FTE employer specialists @ $180K fully loaded each × 18 months + $120K enablement tools) |
| Expected return | 13.0× on $0.9M investment ($11.7M incremental revenue by Month 24) |
| Revenue, year 1 | $3.9M incremental employer outcomes revenue |
| Revenue, year 2 | $11.7M cumulative incremental employer outcomes revenue |
| Revenue, year 3 | $18.5M cumulative if employer cohort grows 15% YoY |
| Exit criteria | Terminate move if employer conversion rate <25% by Month 12 OR if employer at-risk share demanded exceeds 50% OR if device-kit leakage reduction <10 points by Month 18. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Growth Portfolio Framework, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
業界ごとの範囲は容易に見つかりますが、最も役に立たない部分です。範囲内のどの位置に着地するかは、集中度、再現性、オーナー依存度、利益防衛力で決まります。
倍率を動かすことが目的なら、2年から3年必要です。再発収益とオーナー依存度の低減が数字に表れるまで、その程度の期間がかかるためです。
買い手によります。財務的買い手は持続可能なキャッシュフローに支払い、戦略的買い手は自社事業への寄与に支払います。どちらを想定するかで、修正すべき点が変わります。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית